546 jilipark Amgen ( AMGN -7.86% ) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and potential Ozempic competitor MariTide, however, Wall Street wasn’t very impressed. The pharma giant said its weight loss medication helped patients living with obesity or who are overweight lose an average of 20% of their weight in a 52-week trial. For comparison, a clinical trial of Novo Nordisk’s ( NVO +1.54% ) blockbuster weight loss drug Wegovy found that participants lost an average of 15% of their weight after 68 weeks on the drug. Despite potentially being more potent than current drugs on the market, Amgen stock fell over 10% following the news during intraday trading on Tuesday. MariTide belongs to the class of drugs known as GLP-1 medications , made popular by Novo Nordisk’s diabetes treatment Ozempic . These drugs mimic a hormone that regulates appetite and blood sugar and have become highly sought after as treatments for obesity and Type 2 diabetes. Popular brands on the market include Wegovy and Eli Lilly’s ( LLY +5.38% ) Zepbound. Ozempic and prescription weight-loss drugs: How they work, what they cost, side effects, and everything to know Morgan Stanley ( MS -2.08% ) analysts anticipate the global market for GLP-1 treatment will reach $105 billion by 2030, but that will hinge on patient access. With that much money at stake, pharmaceutical companies including Pfizer ( PFE -1.74% ), Viking Therapeutics ( VKTX +2.44% ), and Zealand Pharma, are all racing to enter the lucrative weight-loss drug market. “We are very excited by MariTide’s differentiated profile, with clinically meaningful attributes of substantial and progressive weight loss, monthly or less frequent dosing, significant improvements in cardiometabolic parameters and strong reduction of HbA1C,” said Amgen Chief Scientific Officer James E. Bradner in a press release . Bradner previously told investors that MariTide is expected to be sold in a “convenient, handheld, patient-friendly auto-injector device with a monthly or even less frequent single-injection administration.” This is opposed to the weekly injections required for weight-loss drugs currently on the market. The company is already planning a larger phase 3 trial for the drug. Still, the trial’s results came in at the lower end of Wall Street’s expectations. “Weight loss of 20% meets the bar, but there is a catch,” wrote Wells Fargo Securities ( WFC +1.18% ) analyst Mohit Bansal in a note this morning. “Investors were looking for a minimum 20% weight loss at the highest dose since Zepbound crosses this bar and also newer injectable treatments such as Cagrisema and Retatrutide are expected to be at 25% or higher weight loss.” Jefferies ( JEF -0.32% ) analyst Michael Yee wrote today in a note the the market overreacted and expects Amgen stock to rebound — even if not immediately — once Wall Street digests the results. Yee added, that the data suggests that the MariTide could lead to more weight loss beyond 52 weeks and that less frequent dosing, whether monthly or quarterly, could make it a competitive option. Similarity, Goldman Sachs ( GS -0.14% ) analyst Salveen Richter wrote that he continues to see “a highly differentiated asset and remain[s] confident in the outlook for MariTide” as it advances to a late-stage trial. 📬 Sign up for the Daily Brief Our free, fast, and fun briefing on the global economy, delivered every weekday morning.

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Glaukos GKOS in the last three months. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 1 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Glaukos, revealing an average target of $147.2, a high estimate of $152.00, and a low estimate of $145.00. Observing a 8.24% increase, the current average has risen from the previous average price target of $136.00. Understanding Analyst Ratings: A Comprehensive Breakdown A clear picture of Glaukos's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Ryan Zimmerman BTIG Raises Buy $149.00 $140.00 Allen Gong JP Morgan Raises Overweight $145.00 $130.00 Larry Biegelsen Wells Fargo Raises Overweight $145.00 $135.00 Richard Newitter Truist Securities Raises Buy $152.00 $145.00 Thomas Stephan Stifel Raises Buy $145.00 $130.00 Key Insights: Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Glaukos. This information provides a snapshot of how analysts perceive the current state of the company. Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Glaukos compared to the broader market. Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Glaukos's stock. This comparison reveals trends in analysts' expectations over time. Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Glaukos's market standing. Stay informed and make well-considered decisions with our Ratings Table. Stay up to date on Glaukos analyst ratings. Unveiling the Story Behind Glaukos Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. A Deep Dive into Glaukos's Financials Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity. Revenue Growth: Glaukos's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 23.86% . This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector. Net Margin: Glaukos's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -22.15%, the company may encounter challenges in effective cost control. Return on Equity (ROE): Glaukos's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -3.21%, the company may face hurdles in generating optimal returns for shareholders. Return on Assets (ROA): Glaukos's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -2.32%, the company may face hurdles in generating optimal returns from its assets. Debt Management: With a below-average debt-to-equity ratio of 0.24 , Glaukos adopts a prudent financial strategy, indicating a balanced approach to debt management. The Significance of Analyst Ratings Explained Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are. Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update. Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights. Which Stocks Are Analysts Recommending Now? Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market . This article was generated by Benzinga's automated content engine and reviewed by an editor. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.NEW YORK (AP) — A slide for market superstar Nvidia on Monday knocked Wall Street off its big rally and helped drag U.S. stock indexes down from their records. The S&P 500 fell 0.6%, coming off its 57th all-time high of the year so far. The Dow Jones Industrial Average dipped 240 points, or 0.5%, and the Nasdaq composite pulled back 0.6% from its own record. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get any of our free email newsletters — news headlines, obituaries, sports, and more.NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=113425&from=3 CLASS PERIOD: February 6, 2024 to July 24, 2024 ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning Edwards’ expected revenue for the fiscal year 2024, particularly as it related to the growth of the Company’s core product, Transcatheter Aortic Valve Replacement (“TAVR”). Defendants’ statements included, among other things, strong commitment to the TAVR platform, confidence in the Company’s ability to capitalize on a subset of untreated patients through scaling of its various patient activation activities, and continued claims of significant demand in allegedly lower-penetrated markets. On July 24, 2024, Edwards unveiled below-expectation financial results for the second quarter of fiscal 2024 and, in particular, slashed its revenue guidance for the TAVR platform for the full fiscal year 2024. The Company attributed the TAVR setback on the “continued growth and expansion of structural heart therapies ... [which] put pressure on hospital workflows.” Investors understood this to mean that developments in new procedures, including defendant’s own Transcatheter Mitral and Tricuspid Therapies (“TMTT”), put significant strain on hospital structural heart teams such that they were underutilizing TAVR, despite the Company’s continued claim of a significantly undertreated patient population. Moreover, the Company announced three acquisitions during the second quarter designed to embolden their treatments alternative to TAVR, suggesting further that the company was aware of the potential for the TAVR platform’s decelerated growth. Investors and analysts reacted immediately to Edwards’ revelations. The price of Edwards’ common stock declined dramatically. From a closing market price of $86.95 per share on July 24, 2024, Edwards’ stock price fell to $59.70 per share on July 25, 2024, a decline of about 31.34% in the span of just a single day. DEADLINE: December 13, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=113425&from=3 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of EW during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is December 13, 2024. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: dg@securitiesclasslaw.com Phone: (646) 453-8903

SAN ANTONIO , Nov. 22, 2024 /PRNewswire/ -- The 2025 Hyundai Santa Cruz XRT has been named the Compact Truck of Texas at the Texas Auto Writers Association (TAWA) annual Truck Rodeo held Sept. 26-27, 2024 . The TAWA Texas Truck Rodeo is a prominent annual event where top automotive media evaluate new vehicles based on performance, value, and overall appeal. Competing against strong contenders, the updated 2025 Santa Cruz XRT impressed judges with its rugged design, advanced technology, and enhanced off-road capability. "We are thrilled to see the 2025 Hyundai Santa Cruz XRT recognized as the 'Compact Truck of Texas .' This award reflects our commitment to offering customers a versatile, fun-to-drive vehicle that is not only capable off-road but also packed with cutting-edge technology and design," said Ricky Lao , director of product planning, Hyundai Motor North America. "The Santa Cruz XRT brings together rugged capability with advanced safety features, making it the perfect choice for adventure-minded consumers seeking the best of both worlds." "The Texas Truck Rodeo is a premier event where vehicles are put to the test by seasoned automotive journalists, and the competition this year was fierce. The 2025 Hyundai Santa Cruz XRT stood out for its impressive blend of rugged off-road capability, cutting-edge technology, and unique design," said Cory Fourniquet , president, Texas Auto Writers Association. "This recognition as the 'Compact Truck of Texas' is well-deserved and highlights Hyundai's commitment to delivering versatile and innovative vehicles that meet the needs of Texas drivers." The 2025 Santa Cruz XRT, featuring a new aggressive front design, XRT-exclusive enhancements including front tow hooks, all-terrain tires, and wrench-inspired wheels, sets a new standard. The model's updated interior boasts a panoramic curved display with an available 12.3-inch driver information cluster and infotainment touchscreen display, alongside standard wireless Apple CarPlay® and Android AutoTM, providing an intuitivedriving experience. Hyundai Motor America Hyundai Motor America offers U.S. consumers a technology-rich lineup of cars, SUVs, and electrified vehicles, while supporting Hyundai Motor Company's Progress for Humanity vision. Hyundai has significant operations in the U.S., including its North American headquarters in California , the Hyundai Motor Manufacturing Alabama assembly plant, the all-new Hyundai Motor Group Metaplant America, and several cutting-edge R&D facilities. These operations, combined with those of Hyundai's 835 independent dealers, contribute $20.1 billion annually and 190,000 jobs to the U.S. economy, according to a recent economic impact report . For more information, visit www.hyundainews.com . Hyundai Motor America on Twitter | YouTube | Facebook | Instagram | LinkedIn | TikTok View original content to download multimedia: https://www.prnewswire.com/news-releases/2025-hyundai-santa-cruz-xrt-named-compact-truck-of-texas-at-texas-auto-writers-associations-truck-rodeo-302314024.html SOURCE HyundaiThe NFL could see its second snow game of the 2024 season this Sunday in Buffalo. Last Thursday's Browns-Steelers game featured heavy snow in the second half and it made for some awesome plays and great photos. This Sunday's 49ers-Bills game in Orchard Park could also see some snow, which would favor the Bills since they're used to playing in the cold while the 49ers aren't. This news has NFL fans fired up since snow games are so fun to watch. Bills/IG "Six inches of snow is common in Buffalo (so meh whatever unimpressed), but nothing beats the magic of snow globe football here—it’s as romantic as it is beautiful. Pretty sure I went on a long rant on air about my love of snow globe football in Buffalo with @dandakich once," one tweet read . "Tired of the people wanting domes for every stadium. FOOTBALL WEATHER really is any inclement weather and is an integral part of the game and its history. Some of the most magical moments happened in inclement weather Hot take: We need less dome stadiums," another tweet read . "A reminder, football fundamentally changes at Thanksgiving, let’s do this thing," another tweet read . "Snow games are good when your team isn’t playing in it," another tweet read . The exact snow forecast will continue to get refined since we're still four days away from this game taking place. It's a big one for the 49ers since they have a 5-6 record and need a win to stay alive in the NFC playoff race. Meanwhile, the Bills are trying to keep pace with the Chiefs for the No. 1 spot in the AFC. Kickoff will be at 8:20 p.m. ET on NBC. Related: Snow In Forecast For Big Week 13 NFL Game On Sunday

Football: Fairview’s title hopes fall short in the semis

Pop Watson helps Hokies become bowl eligible with 37-17 victory over rival VirginiaLAS VEGAS (AP) — Formula 1 on Monday at last said it will expand its grid in 2026 to make room for an American team that is partnered with General Motors. “As the pinnacle of motorsports, F1 demands boundary-pushing innovation and excellence. It’s an honor for General Motors and Cadillac to join the world’s premier racing series, and we’re committed to competing with passion and integrity to elevate the sport for race fans around the world," GM President Mark Reuss said. "This is a global stage for us to demonstrate GM’s engineering expertise and technology leadership at an entirely new level.” Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

OMAHA, Neb. (AP) — Investor Warren Buffett renewed his Thanksgiving tradition of giving by handing out more than $1.1 billion of Berkshire Hathaway stock to four of his family's foundations Monday, and he offered new details about who will be handing out the rest of his fortune after his death. Buffett has said previously that his three kids will distribute his remaining $147.4 billion fortune in the 10 years after his death, but now he has also designated successors for them because it's possible that Buffett's children could die before giving it all away. He didn't identify the successors, but said his kids all know them and agree they would be good choices.How major US stock indexes fared Monday, 12/9/2024

LAS VEGAS (AP) — Formula 1 on Monday at last said it will expand its grid in 2026 to make room for an American team that is partnered with General Motors. “As the pinnacle of motorsports, F1 demands boundary-pushing innovation and excellence. It’s an honor for General Motors and Cadillac to join the world’s premier racing series, and we’re committed to competing with passion and integrity to elevate the sport for race fans around the world," GM President Mark Reuss said. "This is a global stage for us to demonstrate GM’s engineering expertise and technology leadership at an entirely new level.” The approval ends years of wrangling that launched a U.S. Justice Department investigation into why Colorado-based Liberty Media, the commercial rights holder of F1, would not approve the team initially started by Michael Andretti. Andretti in September stepped aside from leading his namesake organization, so the 11th team will be called Cadillac F1 and be run by new Andretti Global majority owners Dan Towriss and Mark Walter. The team will use Ferrari engines its first two years until GM has a Cadillac engine built for competition in time for the 2028 season. Towriss is the the CEO and president of Group 1001 and entered motorsports via Andretti's IndyCar team when he signed on financial savings platform Gainbridge as a sponsor. Towriss is now a major part of the motorsports scene with ownership stakes in both Spire Motorsports' NASCAR team and Wayne Taylor Racing's sports car team. Walter is the chief executive of financial services firm Guggenheim Partners and the controlling owner of both the World Series champion Los Angeles Dodgers and Premier League club Chelsea. “We’re excited to partner with General Motors in bringing a dynamic presence to Formula 1," Towriss said. “Together, we’re assembling a world-class team that will embody American innovation and deliver unforgettable moments to race fans around the world.” Mario Andretti, the 1978 F1 world champion, will have an ambassador role with Cadillac F1. But his son, Michael, will have no official position with the organization now that he has scaled back his involvement with Andretti Global. “The Cadillac F1 Team is made up of a strong group of people that have worked tirelessly to build an American works team,” Michael Andretti posted on social media. “I’m very proud of the hard work they have put in and congratulate all involved on this momentous next step. I will be cheering for you!” The approval has been in works for weeks but was held until after last weekend's Las Vegas Grand Prix to not overshadow the showcase event of the Liberty Media portfolio. Max Verstappen won his fourth consecutive championship in Saturday night's race, the third and final stop in the United States for the top motorsports series in the world. Grid expansion in F1 is both infrequent and often unsuccessful. Four teams were granted entries in 2010 that should have pushed the grid to 13 teams and 26 cars for the first time since 1995. One team never made it to the grid and the other three had vanished by 2017. There is only one American team on the current F1 grid — owned by California businessman Gene Haas — but it is not particularly competitive and does not field American drivers. Andretti’s dream was to field a truly American team with American drivers. The fight to add this team has been going on for three-plus years and F1 initially denied the application despite approval from F1 sanctioning body FIA . The existing 10 teams, who have no voice in the matter, also largely opposed expansion because of the dilution in prize money and the billions of dollars they’ve already invested in the series. Andretti in 2020 tried and failed to buy the existing Sauber team. From there, he applied for grid expansion and partnered with GM, the top-selling manufacturer in the United States. The inclusion of GM was championed by the FIA and president Mohammed Ben Sulayem, who said Michael Andretti’s application was the only one of seven applicants to meet all required criteria to expand F1’s current grid. “General Motors is a huge global brand and powerhouse in the OEM world and is working with impressive partners," Ben Sulayem said Monday. "I am fully supportive of the efforts made by the FIA, Formula 1, GM and the team to maintain dialogue and work towards this outcome of an agreement in principle to progress this application." Despite the FIA's acceptance of Andretti and General Motors from the start, F1 wasn't interested in Andretti — but did want GM. At one point, F1 asked GM to find another team to partner with besides Andretti. GM refused and F1 said it would revisit the Andretti application if and when Cadillac had an engine ready to compete. “Formula 1 has maintained a dialogue with General Motors, and its partners at TWG Global, regarding the viability of an entry following the commercial assessment and decision made by Formula 1 in January 2024,” F1 said in a statement. “Over the course of this year, they have achieved operational milestones and made clear their commitment to brand the 11th team GM/Cadillac, and that GM will enter as an engine supplier at a later time. Formula 1 is therefore pleased to move forward with this application process." Yet another major shift in the debate over grid expansion occurred earlier this month with the announced resignation of Liberty Media CEO Greg Maffei, who was largely believed to be one of the biggest opponents of the Andretti entry. “With Formula 1’s continued growth plans in the US, we have always believed that welcoming an impressive US brand like GM/Cadillac to the grid and GM as a future power unit supplier could bring additional value and interest to the sport," Maffei said. "We credit the leadership of General Motors and their partners with significant progress in their readiness to enter Formula 1." AP auto racing: https://apnews.com/hub/auto-racingPhoenix Suns vs. Los Angeles Lakers: How to watch, schedule, live stream info, start time, TV channel

NoneNASA Awards Test Operations ContractNEW YORK (AP) — U.S. stocks rose to records Tuesday after Donald Trump’s latest talk about tariffs created only some ripples on Wall Street, even if they could roil the global economy were they to take effect. The S&P 500 climbed 0.6% to top the all-time high it set a couple weeks ago. The Dow Jones Industrial Average added 123 points, or 0.3%, to its own record set the day before, while the Nasdaq composite gained 0.6% as Microsoft and Big Tech led the way. Stock markets abroad mostly fell after President-elect Trump said he plans to impose sweeping new tariffs on Mexico, Canada and China once he takes office. But the movements were mostly modest. Stock indexes were down 0.1% in Shanghai and nearly flat in Hong Kong, while Canada’s main index edged down by less than 0.1%. Trump has often praised the use of tariffs , but investors are weighing whether his latest threat will actually become policy or is just an opening point for negotiations. For now, the market seems to be taking it more as the latter. The consequences otherwise for markets and the global economy could be painful. Unless the United States can prepare alternatives for the autos, energy products and other goods that come from Mexico, Canada and China, such tariffs would raise the price of imported items all at once and make households poorer, according to Carl Weinberg and Rubeela Farooqi, economists at High Frequency Economics. They would also hurt profit margins for U.S. companies, while raising the threat of retaliatory tariffs by other countries. And unlike tariffs in Trump’s first term, his latest proposal would affect products across the board. General Motors sank 9%, and Ford Motor fell 2.6% because both import automobiles from Mexico. Constellation Brands, which sells Modelo and other Mexican beer brands in the United States, dropped 3.3%. The value of the Mexican peso fell 1.8% against the U.S. dollar. Beyond the pain such tariffs would cause U.S. households and businesses, they could also push the Federal Reserve to slow or even halt its cuts to interest rates. The Fed had just begun easing its main interest rate from a two-decade high a couple months ago to offer support for the job market . While lower interest rates can boost the economy, they can also offer more fuel for inflation. “Many” officials at the Fed’s last meeting earlier this month said they should lower rates gradually, according to minutes of the meeting released Tuesday afternoon. The talk about tariffs overshadowed another mixed set of profit reports from U.S. retailers that answered few questions about how much more shoppers can keep spending. They’ll need to stay resilient after helping the economy avoid a recession, despite the high interest rates imposed by the Fed to get inflation under control. A report on Tuesday from the Conference Board said confidence among U.S. consumers improved in November, but not by as much as economists expected. Kohl’s tumbled 17% after its results for the latest quarter fell short of analysts’ expectations. CEO Tom Kingsbury said sales remain soft for apparel and footwear. A day earlier, Kingsbury said he plans to step down as CEO in January. Ashley Buchanan, CEO of Michaels and a retail veteran, will replace him. Best Buy fell 4.9% after likewise falling short of analysts’ expectations. Dick’s Sporting Goods topped forecasts for the latest quarter thanks to a strong back-to-school season, but its stock lost an early gain to fall 1.4%. Still, more stocks rose in the S&P 500 than fell. J.M. Smucker had one of the biggest gains and climbed 5.7% after topping analysts’ expectations for the latest quarter. CEO Mark Smucker credited strength for its Uncrustables, Meow Mix, Café Bustelo and Jif brands. Big Tech stocks also helped prop up U.S. indexes. Gains of 3.2% for Amazon and 2.2% for Microsoft were the two strongest forces lifting the S&P 500. All told, the S&P 500 rose 34.26 points to 6,021.63. The Dow gained 123.74 to 44,860.31, and the Nasdaq composite climbed 119.46 to 19,174.30. In the bond market, Treasury yields held relatively steady following their big drop from a day before driven by relief following Trump’s pick for Treasury secretary. The yield on the 10-year Treasury inched up to 4.29% from 4.28% late Monday, but it’s still well below the 4.41% level where it ended last week. In the crypto market, bitcoin continued to pull back after topping $99,000 for the first time late last week. It’s since dipped back toward $91,000, according to CoinDesk. It’s a sharp turnaround from the bonanza that initially took over the crypto market following Trump’s election. That boom had also appeared to have spilled into some corners of the stock market. Strategists at Barclays Capital pointed to stocks of unprofitable companies, along with other areas that can be caught up in bursts of optimism by smaller-pocketed “retail” investors. AP Business Writer Elaine Kurtenbach contributed.

Suder scores 16 as Miami (Ohio) downs Mercer 75-72US to transform white elephant destroyers by fitting hypersonic weaponsA bid by The Onion satirical news outlet to buy Alex Jones' conspiracy theory platform Infowars returned Monday to a Texas courtroom, where a judge heard arguments on whether a bankruptcy auction was properly run as Jones alleges collusion and fraud. U.S. Bankruptcy Judge Christopher Lopez in Houston is looking into the November auction and how a trustee chose The Onion over the only other bidder — a company affiliated with Jones that offered twice as much money as The Onion. The judge said the hearing would last into Monday evening and pick up again on Tuesday afternoon. The sale of Infowars is part of Jones' personal bankruptcy case , which he filed in late 2022 after he was ordered to pay nearly $1.5 billion in defamation lawsuits in Connecticut and Texas filed by relatives of victims of the Sandy Hook Elementary School shooting in Connecticut. Jones repeatedly called the 2012 shooting that killed 20 children and six educators a hoax staged by actors and aimed at increasing gun control. Most of the proceeds from the sale of Infowars, as well as many of Jones' personal assets, will go to the Sandy Hook families to help satisfy judgments issued by juries and judges in state courts in Connecticut and Texas. Some proceeds will go to Jones' other creditors. The Onion, which wants to turn Infowars' website and social media accounts into parodies , offered $1.75 million for Infowars' assets in the auction, while First United American Companies — which runs a website in Jones’ name that sells nutritional supplements — bid $3.5 million. The Onion's bid also included a pledge by many of the Sandy Hook families to forgo some or all of the auction proceeds due to them to give other creditors a total of $100,000 more than they would receive under other bids. The trustee, Christopher Murray, chose The Onion, saying its proposal was better for creditors because they would receive more money. Joshua Wolfshohl, an attorney for Murray, told the judge Monday that no wrongdoing occurred during the auction. He called the complaints by Jones and First United American Companies unfounded. “The vast majority of their complaints are just fantastic, imagined conspiracy theories that have no basis in reality," he said. Jones' lawyer, Ben Broocks, questioned Murray's rationale for choosing The Onion and alleged that a recent deposition of the trustee showed improprieties. He also questioned the validity of The Onion's bid, saying it was technically valued at $7 million because of the incentive offered by the Sandy Hook families. An auction company executive involved in the sale testified most of the afternoon. In court filings, Jones and First United American Companies accused Murray, The Onion and the Sandy Hook families of illegally colluding on the bidding, committing fraud and violating the judge's rules for the auction. Murray, The Onion and the families deny the allegations. In his own court filing, Murray called the allegations “a disappointed bidder’s improper attempt to influence an otherwise fair and open auction process.” Up for sale at the auction were all the equipment and other assets in the Infowars studio in Austin, Texas, as well as its social media accounts, websites, video archive and product trademarks. Jones uses the studio to broadcast his far-right, conspiracy theory-filled shows on the Infowars website, his account on the social platform X and radio stations. Jones has set up another studio, websites and social media accounts in case The Onion wins approval to buy Infowars and kicks him out. Jones has said he could continue using the Infowars platforms if the auction winner is friendly to him. Jones is appealing the $1.5 billion in judgments citing free speech rights but has acknowledged that the school shooting happened . On Friday, a Connecticut appeals court reduced by $150 million the original $1.44 billion judgment against Jones in the lawsuit against him in that state, but upheld the rest of the award. Jones' lawyer said he will ask Connecticut's highest court to review the appellate ruling. Jones is also appealing a $50 million judgment in a similar Texas defamation lawsuit.